CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

AbbVie expands Oxford R&D facility as part of £120 million-plus investment

By Reuters News

Nov 4 (Reuters) - AbbVie ABBV.N has expanded its UK research and development facility in Oxford as part of a more than £120 million ($161 million) investment, the US drugmaker said on Wednesday.

The investment comes a few months after the US and Britain finalised an agreement aimed at increasing UK medicine prices in line with President Donald Trump's new US pricing policies.


Here are more details:

  • The new 12,000-square-foot site, known as AbbVie Oxford, will broaden its research capabilities across immunology, neuroscience and oncology

  • The facility builds on capabilities gained through the 2022 acquisition of Oxford-based biotechnology company DJS Antibodies

  • The investment will support research focused on identifying new disease targets and combination therapies in areas with significant unmet medical need

  • AbbVie works with more than 100 universities and research organisations in the UK each year and is expanding collaborations with academic institutions, including the University of Oxford

  • One collaboration with the University of Oxford is studying how patients with certain inflammatory diseases respond to treatments over the course of their illness, aiming to help guide future drug development

  • AbbVie employs more than 1,100 people across its UK operations in Oxford, Maidenhead and Marlow


($1 = 0.7453 pounds)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.